UNSPSC 51313421: Chlorphenamine maleate

This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V1Q0O9OJ9Z. European Medicines Agency schedules Chlorphenamine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01243MIG. Chlorphenamine maleate generally arises in the molecular formula C16H19CLN2.C4H4O4. The term 'chlorphenamine maleate' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule chlorphenamine maleate under HS 29333999.

SMILES: CN(C)CCC(C1CCC(CC1)CL)C2CCCCN2.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51313421 Chlorphenamine maleate is a Commodity code for pharmaceutical active ingredients and finished-form antihistamines, but recent state and local solicitations tagged with this code do not reflect the narrow scope of chlorphenamine maleate procurement. Instead, the tagged opportunities show broader pharmaceutical sourcing: Seminole County, Florida is procuring naloxone and drug deactivation systems through competitive bidding; Texas HHS Commission has issued a Request for Information to solicit vendor capabilities for direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is establishing multiple contracts for generic multi-source pharmaceuticals and over-the-counter products across participating state and local government facilities. The issuing bodies include county health departments, state health and human services agencies, and multi-state cooperative purchasing alliances that aggregate demand across member jurisdictions. The scope of work under these opportunities spans emergency medications (naloxone), generic pharmaceuticals with specific National Drug Codes, and OTC products distributed through authorized wholesalers, reflecting procurement patterns driven by public health initiatives, Medicaid and employee health programs, and emergency-response readiness.

Geographic activity centers on Florida, Texas, and Minnesota, with the MMCAP solicitation extending to Oregon and other participating jurisdictions. The most recent substantial opportunity is Seminole County's IFB 60459723LAS, posted June 30, 2026, with a response deadline of July 26, 2023, for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, requiring vendors to submit bids electronically and include all shipping and delivery costs. MMCAP's RFP (S1070000015802) posted January 20, 2026, with proposals due March 26, 2026, seeks manufacturers to supply generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with awarded vendors effective July 1, 2026, and evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing for the contract term, and 5 percent each on administrative fee compliance, EDI capability, and administrative fee acceptance. Texas HHS's RFI (HHS0017013), posted April 3, 2026, explores direct-to-manufacturer prescription program capabilities but does not commit to formal contract awards at this stage. The code shows limited recent activity directly matching chlorphenamine maleate, suggesting that state and local procurement under this specific pharmaceutical ingredient is not currently visible in public solicitations.